Fig. 1

QC6352 served as a potential pro-senescence agent in gastric cancer harboring TP53 mutations A-B NCI-N87 was treated with low dose genotoxic agents, followed by immunoblotting analysis as indicated. C Flow chart of the novel screening strategy for pro-senescence drugs. D Cells were seeded onto 96-well plates, followed by sequential treatment with individual inhibitors from the Epigenetics Compound Library (10 nM) and DMSO or SSK1 (1 μM). After 96 h, the cell viability was determined by Cell Counting Kit-8 (CCK-8) assays and the heatmap summarized cell viabilities under the indicated treatment. The details of related compounds in this figure are listed in Additional file 1: Table s1